Craig Teller
Expertise in
10
conditions

Dr. Craig Teller

Dermatology
6565 West Loop South, Ste 800, 
Bellaire, TX 
35 Years of Experience
Referral may be required
Expertise in
10
conditions
6565 West Loop South, Ste 800, 
Bellaire, TX 

Overview

Craig Teller is a Dermatologist practicing medicine in Bellaire, Texas. He has been practicing medicine for over 35 years.

Dr. Teller is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Intertrigo, Warts, and Seborrheic Keratosis.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 11 clinical trials.

Graduate Institution

McGovern Medical School At UTHealth, 1991

Residency

University of Texas at Houston

Specialties

Dermatology

Licenses

Dermatology in TX

Hospital Affiliations

Memorial Hermann Southwest Hospital

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

6565 West Loop South, Ste 800, Bellaire, TX 77401

Additional Areas of Focus

Dr. Teller has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Varicose Veins
Acne

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

15 Total Publications

How does canine atopic dermatitis provide a unique opportunity to study spectrum of care?
How does canine atopic dermatitis provide a unique opportunity to study spectrum of care?
Journal: Journal of the American Veterinary Medical Association
Published: December 01, 2025
Similar Doctors
Expertise in
39
conditions
Dr. Stephen Tyring
Dermatology
Expertise in
39
conditions
Dr. Stephen Tyring
Dermatology
Referral may be required
451 N Texas Ave, 
Webster, TX 
 (23.3 miles away)
281-333-3376
Experience:
43+ years
Languages Spoken:
English, German, Spanish
See accepted insurances

Stephen Tyring is a Dermatologist practicing medicine in Webster, Texas. He has been practicing medicine for over 43 years. Dr. Tyring is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Shingles, Plaque Psoriasis, Warts, and Psoriasis.

Expertise in
9
conditions
Dr. Michael Migden
Dermatology
Expertise in
9
conditions
Dr. Michael Migden
Dermatology
Referral may be required
6500 West Loop South, Ste 200 A, 
Bellaire, TX 
 (0.4 miles away)
713-500-8260
Experience:
29+ years
Languages Spoken:
English
See accepted insurances

Michael Migden is a Dermatologist practicing medicine in Bellaire, Texas. He has been practicing medicine for over 29 years. Dr. Migden is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

DermSurgery Associates

6700 West Loop S Ste 500, 
Bellaire, TX 
 (0.4 miles away)
281-817-4975
Languages Spoken:
English
See accepted insurances

Leonard Goldberg is a Dermatologist practicing medicine in Bellaire, Texas. Dr. Goldberg is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Actinic Keratosis, and Liver Spots.

Frequently Asked Questions about Dr. Craig Teller

How do I make an appointment with Dr. Craig Teller?

You can book an appointment with Dr. Craig Teller by calling their office at 713-661-4383. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig Teller a top-rated expert for Plaque Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig Teller is classified as an Advanced expert for Plaque Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig Teller specialize in?

While Dr. Craig Teller is a Dermatology, they have specific expertise in Plaque Psoriasis, Intertrigo, and Warts. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Craig Teller participate in research or clinical trials?

Yes. Dr. Craig Teller has published 15 articles and abstracts on conditions like Plaque Psoriasis. You can view a list of Dr. Craig Teller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig Teller accept my insurance?

Dr. Craig Teller accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-661-4383 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teller's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 59 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile